SMARCA2 and plasma cell leukemia: The anti-cancer efficacy of SMARCA2/4 degraders was next evaluated withex vivo patient-derived cells from cases of plasma cellleukemia (PCL), an aggressive form of MM, and chronic myelogenous leukemia(CML).